- letzte 200 News
- Archiv
| Zeit | Aktuelle Nachrichten | Rating | Leser | ||
|---|---|---|---|---|---|
| 11:34 | DUG Technology - Significant boost to order intake in H225 | 147 | DUG Technology's FY25 results confirmed that order intake stepped up in H225, with intake of $45.7m 131% higher half-on-half, resulting in a record order book of $52m at the end of the year. While revenue... ► Artikel lesen | ||
| 11:34 | Topps Tiles - Laying the groundwork for higher growth | 158 | Topps Tiles' (TPT's) diversification into larger addressable markets with more trading brands means it is well-placed to service more products to more customers in more sectors, and with greater efficiency... ► Artikel lesen | ||
| 08:34 | Oncopeptides - Targeted oncology with commercial momentum | 176 | Oncopeptides (ONCO) is a Swedish biotech that aims to develop and commercialise therapies for difficult-to-treat cancers, with a focus on haematological diseases. Its lead product, Pepaxti, was approved... ► Artikel lesen | ||
| Di | Oryzon Genomics - Foray into sickle cell disease | 179 | Oryzon Genomics has announced that the European Medicines Agency (EMA) has provided regulatory clearance for a Phase Ib trial of iadademstat in sickle cell disease. The Phase Ib study (named RESTORE)... ► Artikel lesen | ||
| Di | ProCredit Holding - More cautious amid macroeconomic uncertainty | 341 | ProCredit Holding (PCB) continues to make good progress in building the scale of its loan book, with 7.2% growth in H125 at constant currency (on track to meet management's FY25 guidance of c 12%).... ► Artikel lesen | ||
| Di | The Platform Group - Robust revenue growth and margin delivery | 300 | The Platform Group (TPG) delivered robust growth in H125 as it continues to benefit from a greater presence in more verticals, with more partners (+26% y-o-y) and ultimately serving more customers (+29%).... ► Artikel lesen | ||
| Fr | Verve Group - Short-term impacts of platform unification | 508 | Verve Group's Q225 results show year-on-year growth slowing to 10% (-4% organic), from 32% (16% organic) in Q125, affected by technical challenges over the integration and unification onto a single... ► Artikel lesen | ||
| Fr | PORR Group - Strong order growth set to continue | 348 | PORR Group delivered new orders of €2,510m in Q225 (up 31% y-o-y), driven by several large transport infrastructure project wins. Q225 book-to-bill rose to 1.5x and the order book now stands at €9,421m... ► Artikel lesen | ||
| Fr | International Airlines Group - Resilient growth | 322 | International Airlines Group's (IAG's) H125 results show strong profit growth, expansion in industry-leading margins and solid shareholder returns. Revenue growth is being driven by its premium brands... ► Artikel lesen | ||
| Fr | PWO Group - Focus remains on long-term growth potential | 316 | In H125, PWO's revenues and EBIT margins were lower, mainly due to weak automotive markets. So far, the company has had no problems with the import tariff situation, but it has noticed a slowdown in... ► Artikel lesen | ||
| Fr | Mendus - Steady progress throughout Q225 | 212 | Mendus's Q225 results reflect a period of progress across the pipeline. The lead programme, vididencel in acute myeloid leukaemia (AML), remains on track to be pivotal-stage ready in H225, creating... ► Artikel lesen | ||
| Fr | Herantis Pharma - H125 results reflect Phase Ib progress | 240 | Herantis Pharma has presented its H125 results, which reflect a period of steady progress as its Phase Ib trial, evaluating HER-096 in patients with Parkinson's disease (PD), edges closer to completion.... ► Artikel lesen | ||
| Do | Picton Property Income - A 13.5% Q1 shareholder return | 203 | Picton Property Income (PCTN) delivered a 1.9% NAV total return in Q126, a combination of dividends (116% covered by EPRA earnings) and modest NAV growth. Lease events continue to unlock reversionary... ► Artikel lesen | ||
| Do | NFON - H125 - a reminder that patience is required | 280 | Investors viewing NFON purely as a growth story might well be disappointed in its modest Q225 top-line growth, but they would be missing other factors. NFON is still in the final stages of a multi-year... ► Artikel lesen | ||
| Do | Gresham House Energy Storage Fund - Debt refinancing unlocks growth potential | 183 | On 18 August 2025, Gresham House Energy Storage Fund (GRID) announced the signing of a new debt facility to refinance existing facilities. This reduces the fund's cost of debt and releases capital for... ► Artikel lesen | ||
| Do | Mendus - Clinical activities on track | 213 | Mendus has reported its Q225 results. During the period, it made continued progress on the lead programme (vididencel in acute myeloid leukaemia, AML), which remains on track to be pivotal-stage ready... ► Artikel lesen | ||
| 19.08. | Nanoco Group - Encouraging commercial progress continues | 263 | Nanoco's trading update indicates that the business is making encouraging commercial progress since Dmitry Shashkov took over as CEO in October 2024. If all goes to plan, this should result in further... ► Artikel lesen | ||
| 19.08. | JDC Group - Higher estimates after 60% FMK acquisition | 393 | After the announcement that it has acquired 60% of lead-generating specialist FMK Group (FMK), JDC reported Q2 results last week. Management reiterated the new FY25 and FY26 guidance that was provided... ► Artikel lesen | ||
| 19.08. | Global Fashion Group - Delivered best Q2 profit since FY21 | 432 | Global Fashion Group's (GFG's) H125 results confirm continued growth in its two largest regions, Australia New Zealand (ANZ) and Latin America (LatAm) as they benefit from their prior repositioning... ► Artikel lesen | ||
| 19.08. | Immix Biopharma - Fleshing out the CAR-T strategy | 228 | Immix has published its Q225 results, reflecting a productive period for NXC-201. The US-based NEXICART-2 trial in relapsed/refractory amyloid light chain amyloidosis (r/r ALA) reported an encouraging... ► Artikel lesen | ||
| 15.08. | Herantis Pharma - Last patient visit completed for Phase Ib | 241 | Herantis Pharma has announced that patient visits have been completed for the final cohort from its Phase Ib trial evaluating lead candidate HER-096 in Parkinson's disease (PD). The primary objective... ► Artikel lesen | ||
| 15.08. | PVA TePla - Higher order momentum, guidance tweaked | 519 | In PVA TePla's (PVA's) Q225 results, higher opex, as expected, resulted in lower profits compared to Q224. However, order momentum appears to have gained traction, with an increase in order intake of... ► Artikel lesen | ||
| 15.08. | Basilea Pharmaceutica - New acquisition bolsters antibacterial franchise | 342 | Basilea Pharmaceutica has strengthened its antibacterial pipeline with the acquisition of global rights to the novel, orally administered, Phase-III ready asset, ceftibuten-ledaborbactam etzadroxil.... ► Artikel lesen | ||
| 14.08. | Pan American Silver - Another quarter of record cash flow generation | 460 | Pan American Silver's (PAAS's) Q2 production and AISC for both silver and gold were in line with quarterly guidance. Despite some sequential increase in costs and slightly lower sales, stronger commodity... ► Artikel lesen | ||
| 14.08. | Ocugen - Novel cell therapies for retinal diseases | 508 | Ocugen's modifier gene therapy (MGT) platform is designed to regulate gene expression to restore visual function across both genetically diverse inherited retinal diseases (IRDs) and retinal conditions... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .